Status:

COMPLETED

L-carnitine and Coenzyme Q10 in Relation to the Oxidative Stress, Antioxidant Enzymes Activities, Inflammation, and the Risk of Coronary Artery Disease

Lead Sponsor:

Taichung Veterans General Hospital

Conditions:

Coronary Artery Disease

Eligibility:

All Genders

20-90 years

Phase:

PHASE2

PHASE3

Brief Summary

Cardiovascular disease (CVD) is the leading cause of Taiwan. L-carnitine (LC) and coenzyme Q10 is recognized as lipid soluble antioxidants. The purposes of this study are going to investigate the rela...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of coronary artery disease (CAD): CAD patients were identified as having at least 50% stenosis of one major coronary artery by cardiac catheterization or as have received percutaneous transluminal coronary angioplasty (PTCA).
  • Health subjects: Subjects did not have any illnesses and a history of gastrointestinal disorder, cardiovascular disease (showed normal electrocardiogram), hypertension, hyperlipidemia, liver and renal disease, diabetes, cancer, alcoholism or other metabolic disease and exhibited normal blood biochemical values, including fasting blood glucose \< 6.11 mmol/L, blood urea nitrogen (BUN) \< 7.9 mmol/L, creatinine \< 123.8 umol/L, alkaline phosphates \< 190 U/L, glutamic oxaloacetic transaminase (GOT) \< 35 U/L and glutamic pyruvate transaminase (GPT) \< 45 U/L.
  • Must be able to swallow tablets

Exclusion

  • age \< 20 years old
  • pregnancy women
  • taking antioxidant vitamins supplements

Key Trial Info

Start Date :

January 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2014

Estimated Enrollment :

47 Patients enrolled

Trial Details

Trial ID

NCT01819701

Start Date

January 1 2013

End Date

February 1 2014

Last Update

March 13 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Taichung Verterans General Hospital

Taichung, Taiwan, 40705